Clinical application of targeted next-generation sequencing in severe pneumonia: a retrospective review
Authors' conclusion
The application of tNGS highlights its promise and significance in assessing the effectiveness of clinical interventions and providing guidance for anti-infection therapies for severe pneumonia.
Study context
- Population
- Patients with severe pneumonia treated in the ICU, June 2022 to June 2023
- Participants
- 130 patients
- Comparison
- Targeted next-generation sequencing (tNGS) vs metagenomics next-generation sequencing (mNGS), culture and RT-qPCR, against clinical diagnosis
- Outcome
- Consistency of tNGS, mNGS and culture results with the clinical diagnosis
Performance
As reported in the abstract
Concordance with clinical diagnosis
| Test or model | Value | Concordance rate |
|---|---|---|
| tNGS | over 70% | over 70% |
tNGS
Valueover 70%
Concordance rateover 70%
Further findings
tNGS microbiological surveillance (subgroup: 5 patients with complicated infections) · during treatment
- tNGS results consistent with culture and imaging results
tNGS drug resistance vs culture drug sensitivity
- Agreement in ≈65% of cases
Original publication
Clinical application of targeted next-generation sequencing in severe pneumonia: a retrospective review. Crit Care. Published 8 July 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →